Shenzhen Edge Medical Co., Ltd. (Edge Medical-B) reported the first transaction under its newly approved share-repurchase mandate, acquiring 202,700 H shares on 26 June 2026 through on-market purchases at the Stock Exchange of Hong Kong.

Key transaction details • Volume: 202,700 H shares, equivalent to 0.06% of the company’s issued share capital (excluding treasury shares) prior to the trade. • Price range: HK$35.70–HK$37.50 per share, with a volume-weighted average repurchase price of HK$37.48. • Cash outlay: HK$7.60 million. • Treasury impact: Treasury share balance rose to 1,818,900 shares, while outstanding issued shares decreased to 325.94 million. Total issued shares remain at 327.76 million pending any future cancellations.

Mandate utilisation • The buyback was conducted under a mandate approved on 25 June 2026 authorising the repurchase of up to 32.61 million shares. • Shares bought to date represent 0.06% of the authorisation, leaving capacity for an additional 32.41 million shares. • In accordance with Hong Kong listing rules, Edge Medical-B is subject to a 30-day moratorium—until 26 July 2026—on issuing new shares or disposing of treasury shares.

Capital structure snapshot (post-transaction, 26 June 2026) • Issued shares (excluding treasury): 325.94 million • Treasury shares: 1.82 million • Total issued shares: 327.76 million

No shares repurchased under this transaction have been cancelled; they are being held in treasury. The board confirmed full compliance with Hong Kong listing rules and all applicable legal requirements.